Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Murillo, O. (Oihana) | - |
dc.creator | Arina, A. (Ainhoa) | - |
dc.creator | Hervas-Stubbs, S. (Sandra) | - |
dc.creator | Gupta, A. (Anjana) | - |
dc.creator | McCluskey, B. (Brandon) | - |
dc.creator | Dubrot, J. (Juan) | - |
dc.creator | Palazon, A. (Asís) | - |
dc.creator | Azpilicueta, A. (Arantza) | - |
dc.creator | Ochoa, M.C. (María Carmen) | - |
dc.creator | Alfaro, C. (Carlos) | - |
dc.creator | Solano, S. (Sarai) | - |
dc.creator | Perez-Gracia, J.L. (Jose Luis) | - |
dc.creator | Oyahobi, B.O. (Babatunde O.) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.date.accessioned | 2012-04-24T15:50:25Z | - |
dc.date.available | 2012-04-24T15:50:25Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008 Nov 1;14(21):6895-6906. | es_ES |
dc.identifier.issn | 1557-3265 | - |
dc.identifier.uri | https://hdl.handle.net/10171/21771 | - |
dc.description.abstract | PURPOSE: Eradication of post-treatment residual myeloma cells is needed to prevent relapses, and immunostimulatory monoclonal antibodies (mAb) such as anti-CD137, CTLA-4, CD40, etc., which enhance the immune response against malignancies, represent a means of achieving this purpose. This study explores anti-CD137 mAbs for multiple myeloma treatment in preclinical models of the disease because they safely augment tumor immunity and are in clinical trials for other cancers. EXPERIMENTAL DESIGN: The antitumor effect of anti-CD137 mAb on mouse plasmacytomas derived from HOPC and NS0 cell lines was studied and compared with that of anti-CTLA-4, anti-CD40, and anti-ICAM-2 mAbs. The antitumor effect of anti-CD137 mAb was also examined in a mouse syngeneic disseminated myeloma (5TGM1) model, which more closely resembles human multiple myeloma. Depletions of specific cell populations and gene-targeted mice were used to unravel the requirements for tumor rejection. RESULTS: Agonistic mAb against CD137 and blocking anti-CTLA-4 mAb showed activity against i.p. HOPC tumors, resulting in extended survival of mice that also became immune to rechallenge. Anti-CD137 mAbs induced complete eradications of established s.c. NS0-derived tumors that were dependent on IFN-gamma, natural killer cells, and CD8(+) T lymphocytes. Natural killer cells accumulated in tumor draining lymph nodes and showed increased IFN-gamma production. Antitumor efficacy of anti-CD137 mAb was preserved in CD28-deficient mice despite the fact that CD28 signaling increases the expression of CD137 on CD8(+) T cells. Importantly, anti-CD137 mAb treatment significantly decreased systemic tumor burden in the disseminated 5TGM1 model. CONCLUSIONS: The immune-mediated antitumor activity of anti-CD137 mAb in mouse models holds promise for myeloma treatment in humans. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Association for Cancer Research | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/5K01CA104180-02;5P30CA054174-16 | - |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Adjuvants, Immunologic/therapeutic use | es_ES |
dc.subject | Antibodies, Monoclonal/therapeutic use | es_ES |
dc.subject | Antigens, CD137/immunology | es_ES |
dc.subject | Multiple Myeloma/drug therapy | es_ES |
dc.subject | Plasmacytoma/drug therapy | es_ES |
dc.title | Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://clincancerres.aacrjournals.org/content/14/21/6895 | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
There are no files associated with this item.
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.